Article
Frequency and Implications of High-Risk Pharmacogenomic Phenotypes Identified in a Diverse Australian Pediatric Oncology Cohort.
Clinical and translational science - 1 May 2025
Moore Claire, Halman Andreas, Stenta Tayla, Khatri Dhrita, Williams Elizabeth, Dyas Roxanne, Stolper Julian, Elliott David A, Conyers Rachel
Abstract excerpt
Pharmacogenomics remains underutilized in pediatric oncology, despite the existence of evidence-based guidelines. Implementation of pharmacogenomics-informed prescribing could improve medication safety and efficacy in pediatric oncology patients, who are at high risk of adverse drug reactions. This study examines the prevalence of high-risk pharmacogenomic phenotypes and the prescription of relevant medications...
Topics
Join the communities discussing this publication.